AC Immune to Host Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer's Disease (AD) and the Involvement of Other Misfolded Proteins in AD and Neurodegenerative Diseases
November 01, 2018 05:00 ET
|
AC Immune SA
Key Opinion Leaders to discuss emerging concepts in the development of therapies for Alzheimer's Disease and other neurodegenerative diseasesMeeting scheduled for November 5, 2018, from 12:00pm...
AC Immune Partner Life Molecular Imaging Presents New Clinical Study Results for Tau PET-Tracer 18F-PI-2620
October 29, 2018 06:00 ET
|
AC Immune SA
Study confirms the good performance of tau PET-tracer 18F-PI-2620 in detecting and quantifying tau deposition, a key pathological feature of Alzheimer's disease Results presented at the 11th...
AC Immune SA: New Data Supporting Crenezumab as Potential Alzheimer's Therapy
October 29, 2018 05:00 ET
|
AC Immune SA
Studies show that crenezumab protects neurons from Alzheimer's disease pathologies in vitro and further support the clinical rationale for crenezumab as a potential treatment for Alzheimer's...
AC Immune Selected to Present Progress on its Tau Morphomer Program in the Late Breaking News Session at CTAD Conference in Barcelona
October 25, 2018 04:00 ET
|
AC Immune SA
Lausanne, Switzerland, October 25, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases has...
AC Immune Announces Dr. Andreas Muhs, Chief Scientific Officer, to Take Medical Leave of Absence
October 22, 2018 04:00 ET
|
AC Immune SA
Lausanne, Switzerland, October 22, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today...
AC Immune Announces Important Clinical Milestones for ACI-24 Vaccine in Alzheimer's Disease and Down Syndrome
August 20, 2018 04:00 ET
|
AC Immune SA
Start of Phase 2 trial with ACI-24 in patients with mild Alzheimer's disease; first patient enrolled Recruitment completed for high-dose cohort of Phase 1b study with ACI-24 for Abeta-related...
AC Immune Reports Second Quarter 2018 Financial Results and Corporate Update
August 08, 2018 04:00 ET
|
AC Immune SA
New total cash position of approximately CHF 210 million that is expected to extend cash runway to Q3 2021, excluding potential incoming milestones Financial position strengthened after Q2 close...
AC Immune Announces Successful Closing of Second Subscription Rights Offering
July 31, 2018 16:05 ET
|
AC Immune SA
Gross Proceeds of All Three Offerings of 10 Million Common Shares in Total Aggregate to USD 117.5 Million Lausanne, Switzerland, July 31, 2018 - AC Immune, SA (NASDAQ: ACIU), a Swiss-based,...
New Phase 2 Data Analysis for Crenezumab Presented at Global Alzheimer's Conference Provides Strong Evidence for Engagement of the Principle Abeta Target
July 25, 2018 17:55 ET
|
AC Immune SA
Crenezumab significantly reduces Abeta oligomers in cerebrospinal fluid (CSF) in patients with Alzheimer's disease Strong evidence for principal target engagement of Abeta oligomers, the most...
AC Immune Announces Closing of First Subscription Rights Offering and Primary Offering as well as Full Exercise of Option to Purchase Additional Shares
July 23, 2018 20:30 ET
|
AC Immune SA
Lausanne, Switzerland, July 24, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company focused on neurodegenerative diseases, today announced the closing of...